The Institute of Cancer Research (ICR) is one of the world’s most influential cancer research institutes. Our mission is to make the discoveries that defeat cancer. We have a long and distinguished history of research with a major impact on the outcome for cancer patients. Our unique partnership with The Royal Marsden NHS Foundation Trust (RMH) makes us the largest comprehensive cancer centre in Europe, performing high quality original basic research and translational studies. The ICR was ranked as the UK’s top academic research centre in the 2008 Higher Education Funding Council Research Assessment Exercise. Based on our publication record, citations and impact we rank among the world’s leading cancer research centres. The Cancer Research UK Cancer Therapeutics Unit (CTU), embedded within the Division of Cancer Therapeutics, is a multidisciplinary 'bench to bedside' centre, comprising around 160 staff dedicated to the discovery and development of novel therapeutics for the treatment of cancer. The Cancer Therapeutics Unit’s exciting goal is to discover high quality drug candidates for validated biological targets and to progress these candidates to clinical trial. All the scientific disciplines are in place to make this possible, including medicinal chemistry, biology, drug metabolism and clinical specialists. A postdoctoral position (Ref: 1408041) is now available in our Hit Discovery and Structural Design Team led by Dr Rob van Montfort. The successful candidate will be involved in protein-ligand crystallography, fragment-based screening and structure-based drug design and will be responsible for crystallisation and structural analysis of protein-ligand complexes from one or more of the Unit’s drug discovery programmes. The successful candidate will also be part of the Division of Structural Biology, in which the crystallographers in Dr van Montfort’s team are embedded, and will have access to state of the art crystallisation facilities, in-house X-ray sources and excellent access to synchrotrons. The successful candidate will also interact closely with our biology, computational chemistry and medicinal chemistry teams, and will therefore be expected to work across both our sites in London (Chelsea and Sutton). Applicants must have a PhD in a biological or physical science, and experience in macromolecular crystallography (to include protein biochemistry, protein crystallisation and protein crystallography). Experience in molecular biology, structure-based drug design, and/or biophysics would be an advantage. Starting salary will be in the range £32,492 to £37,397 p.a. inclusive (based on previous experience). Appointment will be on a fixed term contract of 1 year in the first instance. Informal enquiries to [email protected]<mailto:[email protected]> or [email protected]<mailto:[email protected]>. Please DO NOT send your application to Dr van Montfort or Dr Westwood; applications must be submitted via the ICR web site at www.icr.ac.uk<http://www.icr.ac.uk>. Closing date: 18 April 2014.
Dr. Rob van Montfort Team Leader Hit Discovery and Structural Design Sections of Cancer Therapeutics and Structural Biology The Institute of Cancer Research 15 Cotswold Road Sutton SM2 5NG UK Tel: +44-(0)20-8722-4364 (Sutton) +44-(0)20-7153-5142 (Chelsea) Email: [email protected]<mailto:[email protected]> The Institute of Cancer Research: Royal Cancer Hospital, a charitable Company Limited by Guarantee, Registered in England under Company No. 534147 with its Registered Office at 123 Old Brompton Road, London SW7 3RP. This e-mail message is confidential and for use by the addressee only. If the message is received by anyone other than the addressee, please return the message to the sender by replying to it and then delete the message from your computer and network.
